ex_736281.htm

EX-99.2 5 ex_736281.htm EXHIBIT 99.2 ex_736281.htm

Exhibit 99.2

本文件构成《招股说明书》第 10 (a) 条的一部分，涵盖根据1933年《证券法》注册的证券.

Moleculin Biotech，Inc. 2024股票计划

激励型股票期权协议

以下指定的员工已被选入Moleculin Biotech, Inc. 2024年股票计划（“2024计划”）参与者，并已被授予以下概述的激励股票期权：

参与者：

授予日期：

期权覆盖的股票：

期权行使价格： $

到期日：

归属计划： 期权将在授予日期的后续每个__________周年纪念日上以__________等额分期（或者每个分期__________股份）实现（即第一个此类分期将在授予日期的第一个周年纪念日上实现），前提是参与者在该归属日期（们）向公司提供服务。

本协议自上文中所述的授予日期起生效，由特拉华州一家公司Moleculin Biotech, Inc.（以下简称“公司”）和上文提及的参与者之间达成。各方一致同意如下：

2024年计划对统治该期权的条款和条件进行了完整描述。如果本协议的条款与2024年计划的条款存在任何不一致，2024年计划的条款应当适用。所有大写的术语的含义应当按照2024年计划所规定的，除非本协议另有约定。2024年计划的副本附在此处，并2024年计划的条款特此参照并纳入本协议。

1. 股票期权授予根据本文规定和2024计划的条款和条件，并考虑参与者在此提供的协议，公司特此授予参与者购买公司普通股数量的期权，每股行使价格以及上述规定的时间表。授予旨在作为《1986内部收入法典》第422（b）节中描述的激励性股票期权（以下简称“法典”）。

2. 参与者接受行使该期权的前提是参与者接受本协议。

3. 行使选择权根据以下第4节的规定，参与者可以在到期日期之前的任何时间行使期权的已获授权部分。参与者或其在参与者死亡时的个人代表应根据公司董事会薪酬委员会（“委员会”）在行使时期实施的程序，向公司致富金融(临时代码)（或者如果参与者是致富金融(临时代码)，则向首席执行官）书面通知行使期权任何部分的选择。

在行使期权时，行使期权的普通股份购买价格必须通过以下一种或多种方式支付：(a) 现金支付，(b) 通过向证券经纪商支付现金，该证券经纪商已收到参与者提交的行使通知和不可撤销指示，从行使期权的股票销售所得款项中将购买价格交付给公司，(c) 通过指示公司扣留相应数量的普通股份，该普通股份在行使期权时的公允市值等于购买价格的金额和/或 (d) 通过将参与者拥有的其他受公司认可的普通股交付给公司，按其当时的公允市值估价。

在支付完行权价格之前，不得行使期权

如果在日历年度内（根据授予时每个期权确定）执行的部分期权的公允市场价值超过100,000美元，则超出此限制的部分将被视为非合格股票期权。因此，期权的解锁或提前解锁可能导致全部或任何部分期权被视为非合格股票期权。

4. 就业终止时行使权利如果参与者在公司及其所有子公司的雇佣关系未经过其唯一酌情权的委员会确定且无故终止，且非因死亡、伤残或退休等任何原因，那么期权的已归属部分将继续行使，直至参与者终止后的第90天，或期权根据其条款到期为止的较早时间。未在雇佣终止日期之日前获得的期权部分将在该日期到期并不得行使。

如果参与者因死亡、伤残或退休而终止与公司和所有子公司的雇佣关系，则期权的已获得部分将继续行使，直到参与者终止之日起一年后或期权按其条款到期之日（以较早者为准）。未在雇佣终止之日尚未获得的期权部分将在该日期到期，并不得行使。

如果参与者与公司及所有子公司的雇佣关系因公司原因（由委员会自行决定）终止，则期权应在终止当天到期，并在终止当天后不得行使任何部分。

根据本节4的目的，(A)“残疾”一词的含义及确定方式应遵循参与者所参与的公司长期残疾计划中规定的内容，(B)“退休”指参与者在公司和所有子公司无正当理由被终止雇佣（由委员会自行决定）时，参与者年满65岁或55岁以上且在公司及其子公司工作10年及以上。

本第4节前述规定应受参与者与公司签订或可能签订的任何书面雇佣或解雇协议的规定约束，关于行使期权的该雇佣或解雇协议的规定应取代本第4节中任何不一致或相悖的规定。

5. 保密和竞业禁止协议尽管本协议的任何其他条款，在委员会确定参与人违反了参与人与公司之间生效的任何保密和/或竞业禁止协议的任何条款的情况下，（a）无论已经取得或未取得的期权部分（已经归属或未归属）应被取消并归还给公司，以及（b）参与人应在委员会书面通知后的30天内向公司汇款，汇款金额等于此前行使的期权部分所对应的普通股份数量，乘以普通股的公允市值与行权价格之间的差额。公司应有权按照适用法律的规定，从公司可能欠参与人的任何金额中扣除这笔款项。

6. 期权不可转让。该期权可能不得出售、转让、抵押、转让或以其他方式处置或抵押，除非通过遗嘱或根据继承和分配法律。

7. 受益人指定参与者可以随时指定任何受益人（可能是有条件或连续指定的），在其死亡时，任何期权下的受益应支付给受益人。每个指定将撤销参与者以前的所有指定，应采用董事会规定的形式，并只有在参与者生前以书面形式向董事会提交时才有效。如果没有这样的指定，或者如果所有受益人在参与者之前去世，则在参与者死亡时未支付的受益应支付给参与者的遗产。

8. 股东的权利 参与者在行使价格已支付并将股票发行并交付给其之前，对于期权和本协议项下的普通股份没有股东权利。

9. 协议的放弃或更改若选择权涉及全部行使，本协议应送交公司取消。若选择权涉及部分行使或普通股数目或指定股份变更，参与者应将本协议送交公司，以便对其进行适当注记，或根据公司判断的方式，反映指定股份数目或变更。

10. 管理该选项应按委员会不时采纳的行政规定行使。特此明了，委员会被授权管理、解释并做出一切必要或适当的决定，以管理2024计划和本协议，所有这些将对参与者具约束力。

11. 管辖法本协议及选项将在所有方面根据并受特拉华州法律所解释、管理和统治。

* * *

参与者通过接受本协议，同意受其条款约束。

	Moleculin Biotech, Inc.

	By:

	标题:
	参与者

由：

印刷姓名:

本文件构成第10(a)条款的招股说明书的一部分，涵盖根据1933年证券法登记的证券。.

Moleculin Biotech, Inc. 2024 股票计划

非合格股票期权协议（适用于非独立董事以外的个人）

以下所述的员工已被选为Moleculin Biotech, Inc. 2024股票计划（“2024计划”）的参与者，并已被授予如下所述的非合格选择权：

参与者：

授予日期：

选项涵盖的股票：

选择权执行价格： $

到期日:

解约期表： 期权将在设立日期的连续每一周年日期均等分段（或每一段股份）发放，前提是参与者在该解约日期提供服务给公司。

本协议自上文设定的授予日期起生效，由特拉荷马州公司Moleculin Biotech, Inc.（以下简称“公司”）与上述参与者之间缔结。合约双方一致同意：

2024年计划对于控制选项的条款和条件作出完整说明。若本协议条款和2024年计划条款之间存在任何不一致，应以2024年计划的条款为准。所有大写字母条款应具有2024年计划中所赋予的含义，除非另有规定。2024年计划副本已附上，并特此参照并纳入2024年计划条款。

1. Stock Option Grant. Subject to the provisions set forth herein and the terms and conditions of the 2024 Plan, and in consideration of the agreements of the Participant herein provided, the Company hereby grants to the Participant an Option to purchase from the Company the number of shares of Common Stock, at the exercise price per share, and on the schedule, set forth above.

2. Acceptance by Participant. The exercise of the Option is conditioned upon the acceptance of this Agreement by the Participant.

3. Exercise of Option. Subject to Section 4 below, the Participant may exercise the vested portion of the Option at any time prior to the Expiration Date. Written notice of an election to exercise any portion of the Option shall be given by the Participant, or his personal representative in the event of the Participant’s death, to the Company’s Chief Financial Officer (or Chief Executive Officer if the Participant is the Chief Financial Officer), in accordance with procedures established by the Compensation Committee of the Board of Directors of the Company (the “Committee”) as in effect at the time of such exercise.

At the time of exercise of the Option, payment of the purchase price for the shares of Common Stock with respect to which the Option is exercised, and of an amount sufficient to satisfy all minimum Federal, state and local withholding tax requirements, must be made by one or more of the following methods: (a) in cash, (b) in cash received from a broker-dealer to whom the Participant has submitted an exercise notice and irrevocable instructions to deliver the purchase price or withholding tax to the Company from the proceeds of the sale of shares subject to the Option, (c) by directing the Company to withhold such number of shares of Common Stock otherwise issuable upon exercise of the Option with a fair market value equal to the amount of the purchase price or the tax to be withheld and/or (d) by delivery to the Company of other Common Stock owned by the Participant that is acceptable to the Company, valued at its then fair market value.

No shares shall be issued upon exercise of the Option until full payment of the exercise price and tax withholding obligation has been made.

4. Exercise Upon Termination of Employment. If the Participant’s employment with the Company and all subsidiaries terminates without cause (as determined by the Committee in its sole discretion) and for any reason other than death, disability or retirement, the then vested portion of the Option shall continue to be exercisable until the earlier of the 90th day after the date of the Participant’s termination or the date the Option expires by its terms. The portion of the Option not vested as of the date of such termination of employment shall expire as of such date and shall not be exercisable.

If the Participant’s employment with the Company and all subsidiaries terminates due to death, disability or retirement, the then vested portion of the Option shall continue to be exercisable until the earlier of one year after the date of the Participant’s termination or the date the Option expires by its terms. The portion of the Option not vested as of the date of such termination of employment shall expire as of such date and shall not be exercisable.

If the Participant’s employment with the Company and all subsidiaries is terminated by the Company for cause (as determined by the Committee in its sole discretion), the Option shall expire on the date of such termination, and no portion shall be exercisable after the date of such termination.

For purposes of this Section 4, (A) “disability” has the meaning, and will be determined, as set forth in the Company’s long term disability program in which the Participant participates, and (B) “retirement” means the Participant’s termination from employment with the Company and all subsidiaries without cause (as determined by the Committee in its sole discretion) when the Participant is 65 or older or 55 or older with 10 years of service with the Company and its subsidiaries.

The foregoing provisions of this Section 4 shall be subject to the provisions of any written employment or severance agreement that has been or may be executed by the Participant and the Company, and the provisions in such employment or severance agreement concerning exercise of the Option shall supersede any inconsistent or contrary provision of this Section 4.

5. Confidentiality and Non-Compete Agreement. Notwithstanding any other provision of this Agreement, in the event the Committee determines that the Participant has breached any provision of any confidentiality and/or non-compete agreement in effect between the Participant and the Company, (a) the then outstanding and unexercised portion of the Option (whether vested or unvested) shall be cancelled and forfeited back to the Company and (b) the Participant shall remit to the Company within 30 days of written notice from the Committee a cash payment equal to the number of shares of Common Stock subject to the portion of the Option that was previously exercised, multiplied by the excess of the fair market value of the Common Stock on the date of exercise over the Option Exercise Price. The Company shall be entitled, as permitted by applicable law, to deduct the amount of such payment from any amounts the Company may owe to the Participant.

6. Nontransferability of Options. The Option may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution.

7. Beneficiary Designation. The Participant may, from time to time, name any beneficiary or beneficiaries (who may be named contingently or successively) to whom any benefit under the Option is to be paid in the event of his or her death. Each designation will revoke all prior designations by the same Participant, shall be in a form prescribed by the Board, and will be effective only when filed by the Participant in writing with the Board during his or her lifetime. In the absence of any such designation, or if all beneficiaries predecease the Participant, benefits remaining unpaid at the Participant’s death shall be paid to the Participant’s estate.

8. Rights as a Stockholder. The Participant shall have no rights as a stockholder of the Company with respect to the shares of Common Stock subject to the Option and this Agreement until such time as the exercise price has been paid and the shares have been issued and delivered to him or her.

9. Surrender of or Changes to Agreement. In the event the Option shall be exercised in whole, this Agreement shall be surrendered to the Company for cancellation. In the event the Option shall be exercised in part or a change in the number of designation of the shares of Common Stock shall be made, this Agreement shall be delivered by the Participant to the Company for the purpose of making appropriate notation thereon, or of otherwise reflecting, in such manner as the Company shall determine, the change in the number or designation of such shares.

10. Administration. The Option shall be exercised in accordance with such administrative regulations as the Committee shall from time to time adopt. It is expressly understood that the Committee is authorized to administer, construe, and make all determinations necessary or appropriate to the administration of, the 2024 Plan and this Agreement, all of which shall be binding upon the Participant.

11. Governing Law. This Agreement, and the Option, shall be construed, administered and governed in all respects under and by the laws of the State of Delaware.

* * *

参与者通过接受本协议，同意受其条款约束。

	Moleculin Biotech, Inc.


	由：

	职称:

	参与者

由：

印刷姓名:

本文件构成根据1933年证券法下注册的证券章程第10(a)部分。.

Moleculin Biotech, Inc. 2024 股票计划

非员工董事的非合格股票期权协议

以下所指的董事已被选定为Moleculin Biotech, Inc. 2024股票计划（"2024计划"）的参与者，并已按照以下概述授予了一个非合格期权：

参与者：

授予日期：

选项所涵盖的股份：

选择权行使价格： $

到期日:

归属计划： 该选择权将在授予日期之后的四个季度内，以四（4）个相等的季度分期（或每期______股）归属，前提是参与者在这些归属日期仍担任公司的成员。’董事会。

本协议自上文设定的授予日期起生效，由特拉荷马州公司Moleculin Biotech, Inc.（以下简称“公司”）与上述参与者之间缔结。合约双方一致同意：

2024计划提供了关于选项的条款和条件的完整说明。如果本协议的条款与2024计划的条款之间存在任何不一致，则以2024计划的条款为准。所有大写术语应具有2024计划中所赋予的含义，除非本文件中另有规定。2024计划的副本附于本协议，且2024计划的条款在此通过引用纳入本协议。

12. Stock Option Grant. Subject to the provisions set forth herein and the terms and conditions of the 2024 Plan, and in consideration of the agreements of the Participant herein provided, the Company hereby grants to the Participant an Option to purchase from the Company the number of shares of Common Stock, at the exercise price per share, and on the schedule, set forth above.

13. Acceptance by Participant. The exercise of the Option is conditioned upon the acceptance of this Agreement by the Participant.

14. Exercise of Option. Subject to Section 4 below, the Participant may exercise the vested portion of the Option at any time prior to the Expiration Date. Written notice of an election to exercise any portion of the Option shall be given by the Participant, or his personal representative in the event of the Participant’s death, to the Company’s Chief Financial Officer (or Chief Executive Officer if the Participant is the Chief Financial Officer), in accordance with procedures established by the Compensation Committee of the Board of Directors of the Company (the “Committee”) as in effect at the time of such exercise.

No shares shall be issued upon exercise of the Option until full payment of the exercise price and tax withholding obligation has been made.

15. Exercise Upon Termination of Service. If the Participant’s service as a member of the Company’s Board of Directors terminates for any reason other than death, disability or retirement, the then vested portion of the Option shall continue to be exercisable until the earlier of the 90th day after the date of the Participant’s termination or the date the Option expires by its terms. The portion of the Option not vested as of the date of such termination of service shall expire as of such date and shall not be exercisable.

If the Participant’s service as a member of the Company’s Board of Directors terminates due to death, disability or retirement, the then vested portion of the Option shall continue to be exercisable until the earlier of one year after the date of the Participant’s termination or the date the Option expires by its terms. The portion of the Option not vested as of the date of such termination of service shall expire as of such date and shall not be exercisable.

For purposes of this Section 4, (A) “disability” has the meaning, and will be determined, as set forth in the Company’s long term disability program in which the Participant participates, and (B) “retirement” means the Participant’s termination from service as a member of the Company’s Board of Directors when the Participant is 65 or older or 55 or older with 10 years of service with the Company and its subsidiaries.

16. Confidentiality and Non-Compete Agreement. Notwithstanding any other provision of this Agreement, in the event the Committee determines that the Participant has breached any provision of any confidentiality and/or non-compete agreement in effect between the Participant and the Company, (a) the then outstanding and unexercised portion of the Option (whether vested or unvested) shall be cancelled and forfeited back to the Company and (b) the Participant shall remit to the Company within 30 days of written notice from the Committee a cash payment equal to the number of shares of Common Stock subject to the portion of the Option that was previously exercised, multiplied by the excess of the fair market value of the Common Stock on the date of exercise over the Option Exercise Price. The Company shall be entitled, as permitted by applicable law, to deduct the amount of such payment from any amounts the Company may owe to the Participant.

17. Nontransferability of Options. The Option may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution.

18. Beneficiary Designation. The Participant may, from time to time, name any beneficiary or beneficiaries (who may be named contingently or successively) to whom any benefit under the Option is to be paid in the event of his or her death. Each designation will revoke all prior designations by the same Participant, shall be in a form prescribed by the Board, and will be effective only when filed by the Participant in writing with the Board during his or her lifetime. In the absence of any such designation, or if all beneficiaries predecease the Participant, benefits remaining unpaid at the Participant’s death shall be paid to the Participant’s estate.

19. Rights as a Stockholder. The Participant shall have no rights as a stockholder of the Company with respect to the shares of Common Stock subject to the Option and this Agreement until such time as the exercise price has been paid and the shares have been issued and delivered to him or her.

20. Surrender of or Changes to Agreement. In the event the Option shall be exercised in whole, this Agreement shall be surrendered to the Company for cancellation. In the event the Option shall be exercised in part or a change in the number of designation of the shares of Common Stock shall be made, this Agreement shall be delivered by the Participant to the Company for the purpose of making appropriate notation thereon, or of otherwise reflecting, in such manner as the Company shall determine, the change in the number or designation of such shares.

21. Administration. The Option shall be exercised in accordance with such administrative regulations as the Committee shall from time to time adopt. It is expressly understood that the Committee is authorized to administer, construe, and make all determinations necessary or appropriate to the administration of, the 2024 Plan and this Agreement, all of which shall be binding upon the Participant.

22. Governing Law. This Agreement, and the Option, shall be construed, administered and governed in all respects under and by the laws of the State of Delaware.

* * *

参与者通过接受本协议，同意受其条款约束。

	莫科林生物科技股份有限公司


	由:

	职称：

	参与者

由：

印刷姓名:

本文件构成根据1933年证券法下注册的证券章程第10(a)部分。.

Moleculin Biotech, Inc. 2024 股票计划

受限股票 单位奖励合同（适用于重要员工）

Moleculin Biotech, Inc.（德拉瓦州公司，以下称「公司」）特此授予以下名列的关键员工（以下称「受奖人」）一项限制性股票单位（「RSU」）奖励（以下称「奖励」），该奖励与公司的普通股相关：

主要员工         :
奖励日期:
奖励的限制性股票数量:
解除限制期结束日期:

本奖项将受以下条款和条件以及Moleculin Biotech, Inc. 2024股票计划（“2024计划”）的规定约束，该计划的副本已附上随函附上，其条款特此参照并纳入：

1. 授予奖项本公司特此授予受赠人有限股份单位（RSU）奖励。RSU是根据2024计划及本协议的条款和条件，获得一股普通股分配的权利。

2. 受赠者的接受奖项的接收以受赠者在本协议末尾提供的空间接受为条件，并需将签署的本协议副本交回公司的秘书。如果受赠者未能归还此已签署的协议，则受赠者的奖项将被没收给公司。

3. RSU 账户公司应在其帐册上以被授予人的名义维持一个账户（“ RSU 账户”），该账户应反映授予人被授予的 RSU 数量以及根据第 4 条支付给授予人的任何股息等价物。

4. Dividend Equivalents. Upon the payment of any dividends on Common Stock occurring during the period beginning on the date of the Award and ending on the date the RSUs are settled in Common Stock (or the date the RSUs are forfeited), the Company shall credit the Grantee’s RSU Account with an amount equal in value to the dividends that the Grantee would have received had the Grantee been the actual owner of the number of shares of Common Stock represented by the RSUs in the Grantee’s RSU Account on that date. Such amounts shall be paid to the Grantee in cash at the time and to the extent the RSU Account is distributed to the Grantee. Any dividend equivalents relating to RSUs that are forfeited shall also be forfeited.

5. Nontransferability. Except as set forth in Section 12 of the 2024 Plan, neither the Award nor any of the RSUs subject to the Award may be sold, assigned, pledged, encumbered or otherwise transferred, voluntarily or involuntarily. Any attempted sale, assignment, pledge, encumbrance or transfer of the Award, other than in accordance with its terms, shall be void and of no effect.

6. 授予.

(a) 除非以下(b)和(c)所述，受赠人将根据如下所述，获得奖励的资格：_________________________

(b) 若受托人因任何原因与公司及所有附属公司的雇佣终止，则奖励对象的未授权RSUs将被取消并归还给公司，对于这些被取消的RSUs，受托人的权益、标题和利益将自动失效并不再具有任何效力。受托人特此不可撤回地指定并任命公司秘书为受托人的代理人和特许状，代表或代替受托人行事，以受托人的名义签署任何文件和工具，以进一步证明未授予RSUs的没收。

7. 奖励的结算若受让人根据第6款获得授予，自归属日起30天内，公司应分发给受让人，或其个人代表、受益人或遗产，视情况而定，(a)与授予有关的归属RSU数量相等的普通股份，以及(b)根据第4款应支付的股息等值现金支付。

8. 代扣税受赠人应向公司支付足够的金额，以满足所有最低的联邦、州和地方扣缴税要求，然后才能交付任何普通股，这是根据奖励所涵盖的任何已归属限制性股票单位的结算。公司全权酌情可允许支付额外的扣缴税，最多可达法定最高税率。此类税款的支付可以通过以下一种或多种方式进行：（a）以现金方式，（b）以受赠人已向经纪商提交的通知和不可撤回的指示来自经纪商收到的现金，该经纪商将部分可交付于奖励结算的股票的销售收益交给公司，（c）以受赠人拥有的其他普通股，并接受公司的价值，按照其当前公允市值交付给公司，以及/或（d）指示公司扣留可交付于奖励结算的普通股，以其公允市值等于需扣除的税额。

9. 股份交付. 奖励的普通股股份交付将以书记入帐方式记入公司为受赠人设立的账户，该账户由公司的过户代理机构管理；前提是公司应在收到受赠人（或其遗产或法定代表人，视情况而定）的书面请求后，根据受赠人（或其遗产或法定代表人）的名义发出代表该奖励股份的证书。

10. 股东权利 . 选择权持有人在颁发股票证书给予或登记该股份以获得普通股份之前，对于任何选择权部分，将不拥有股东权利。选择权股份将受本协议的条款和条件约束。除本协议或计划另有规定外，在颁发该等证书之前股息或其他权益的日期即早于记录日期的，不会为之作任何调整。选择权持有人通过签署本协议，同意依照公司要求签署与普通股份的颁发相关之文件。. 受让人不得享有与本公司奖励相关的任何股东权利，包括投票权、获取分红派息及其他分配的权利，直到并在奖励以普通股结算时为止。

11. 内幕交易政策在奖项结算后交付的普通股股份的出售或转让，须遵守公司不时生效的内部交易政策。

12. 撤回权不妨让任何其他条款规定，根据适用法律要求，包括多德-弗兰克华尔街改革和消费者保护法案，公司应有权追回所有或任何部分奖励（包括放弃任何未实现的奖项或由受赠人支付给公司已授予奖项股份或等于已授予奖项股份的现金支付）。请求追回的价值将由委员会决定。委员会在适用法律允许的情况下有权从公司可能欠受赠人的任何金额中扣除该支付的金额。

13. 就业状态本协议不赋予受让人作为公司员工的权利。

14. 管理. 奖项应根据委员会不时采纳的相关规定进行管理。

15. Plan Governs. If there is any inconsistency between the terms of this Agreement and the terms of the 2024 Plan, the 2024 Plan’s terms shall govern. All capitalized terms shall have the meanings ascribed to them in the 2024 Plan, unless specifically set forth otherwise herein.

16. Governing Law. This Agreement, and the Award, shall be construed, administered and governed in all respects under and by the laws of the State of Delaware.

IN WITNESS WHEREOF, this Agreement is executed effective as of the ____ day of _____, 20___.

	MOLECULIN BIOTECH, INC.



	By:

AGREED AND ACCEPTED:

I acknowledge receipt of the Moleculin Biotech, Inc. 2024 Stock Plan, and hereby accept this Restricted Stock Unit Award subject to all the terms and conditions thereof. I agree to accept as binding, conclusive and final all decisions and interpretations of the Committee regarding any questions arising under the 2024 Plan or this Award Agreement.

GRANTEE

Print Name:


Signature:


Date: